Over the past decade, oncology has been driven by novel therapies that can cure or control many cancers, allowing more patients to live long enough to experience the potential cardiotoxic effects of their treatments. The key for primary care and oncology clinicians is early detection and correction of cardiovascular risk factors, the close cardiac monitoring during antineoplastic treatment, and awareness of cardiac risk for cancer survivors. This program will help clinicians to apply detection, monitoring and management techniques to improve patient outcomes. Learners who complete the Cardio-Oncology Academy modules will have accessed cutting-edge information regarding the most appropriate and effective treatment for patients who have long-term toxicity-related cardiac dysfunction, including heart failure, valvular dysfunction and autonomic dysfunction.
Available for AMA PRA Category 1 CreditTM, Continuing Nursing Education, and Continuing Pharmacy Education
Radiation-induced Valvular Disease
Radiation therapy is a key component in the curative treatments for certain cancers. However, it is should be followed by regular screening for valvular disease. Here we also look at the areas most effected by radiation and best modalities for diagnosing. Finally, while there are no specific guidelines, multiple approaches to management and valve replacements are reviewed.
Ibrutinib-Induced Atrial Fibrillation
Ibrutinib is a targeted therapy used for treatment with specific types of leukemia and lymphomas. In this course, we look at the association between developing atrial fibrillation and Ibrutinib treatment. This course will help clinicians with assessing risk, management, and prevention of Ibrutinib-Induced Atrial Fibrillation.
Detection and Management of Chemotherapy-induced Cardio-toxicity: Role of Cardiac Biomarkers
The damage from cardiotoxicity can be mitigated if it is discovered and addressed early in oncology treatment. However, identifying cancer therapy related cardiotoxicity can be challenging. This course uses a case-based approach to discuss leveraging left ventricular ejection fraction (LVEF) and serum biomarkers in early screening and detection.
Delayed Cardiac Toxicity Case Related to Hodgkin Lymphoma
During and following chest wall radiation for Hodgkin lymphoma, recognize symptoms of coronary artery disease and other cardiovascular abnormalities. Identify the associated risks of cardiothoracic surgery for patients with a history of chest wall radiation.
Doxorubicin Induced Cardiomyopathy
Doxorubicin is a common chemotherapeutic agent for many cancers, generally in combination with other drugs. While effective in treating cancer in many cases, doxorubicin does have side effects, and one is cardiotoxicity. This course will help clinicians to identify those patients most at risk for cardiotoxicity, both acute and chronic, and provide management strategies.
Stress-Induced Cardiomyopathy in Cancer Patients
Stress-induced cardiomyopathy, or Takotsubo Cardiomyopathy, is a rapidly reversible form of acute heart failure with significantly higher prevalence in cancer populations. This case-based course discusses diagnostic tools and management focusing on complications often found in cancer patients.